Natural Capsules Limited (NSE:NATCAPSUQ) filed an investor presentation on 13 August 2026 under Regulation 30 of SEBI LODR Regulations, 2015, covering unaudited consolidated and standalone financial results for the quarter ended 30 June 2026, reporting consolidated revenue from operations of Rs 48.71 crore and a PAT loss of Rs 5.74 crore.
Key Highlights
- Consolidated revenue from operations for Q1FY27 stood at Rs 48.71 crore, up 8% year-on-year but down 17% quarter-on-quarter compared to Q4FY26's Rs 58.45 crore.
- EBITDA improved sharply to Rs 1.12 crore in Q1FY27 from Rs 0.32 crore in Q1FY26, a 251% year-on-year increase, with EBITDA margins expanding 159 basis points year-on-year to 2.30%.
- The company reported a consolidated PAT loss of Rs 5.74 crore in Q1FY27, with EPS at negative Rs 5.55, both marginally wider than Q1FY26's loss of Rs 5.58 crore and EPS of negative Rs 5.40.
- Management disclosed that an ERP system implementation in the final days of Q1FY27 deferred billing and dispatch of approximately five days of sales into Q2FY27, affecting reported revenue for the quarter.
About the Company
Natural Capsules Limited (NSE:NATCAPSUQ, BSE:524654), headquartered at Trident Towers, Bangalore, is a hard capsule shell manufacturer incorporated in 1993. The company operates two manufacturing units, in Bangalore and Pondicherry, with a capacity of 20.25 billion capsules per annum in FY26. It pioneered vegetarian capsule manufacturing in India and is expanding into API manufacturing through its subsidiary, Natural Biogenex Private Limited.
Announcement in Detail
The investor presentation filed on 13 August 2026 covers Q1FY27 consolidated financials. Revenue from operations rose 8% year-on-year to Rs 48.71 crore, while other income increased to Rs 2.35 crore from Rs 0.36 crore in Q1FY26. Total income for the quarter was Rs 51.06 crore. Finance costs rose 97% year-on-year to Rs 4.97 crore, and depreciation stood at Rs 4.33 crore, contributing to a pre-tax loss of Rs 5.83 crore.
On operations, the company disclosed that one HPMC capsule manufacturing line has been temporarily converted to a gelatine line, with a second conversion expected in the near term, citing erratic US market demand and duty structure uncertainty. The first batch under a contract manufacturing agreement with Fermbox Bio commenced in August 2026, and a new contract manufacturing agreement with a Mumbai-based client was executed during the quarter. Prednisolone synthesis at gram-scale was completed, with a fully backward-integrated batch targeted by end of September 2026.
Impact on Investors
Investors will note that while EBITDA improved significantly year-on-year, the company continues to report a net loss, with PAT at negative Rs 5.74 crore in Q1FY27. Finance costs at Rs 4.97 crore, up 97% year-on-year, represent a material drag on profitability that shareholders will observe in the context of the company's ongoing capacity and API business investments.
The filing shows that the HPMC segment faces near-term headwinds from US market conditions, resulting in line conversions that alter the product mix. The disclosed ERP-related dispatch deferral means that Q1FY27 reported revenue understates operational output to some degree, as the company itself acknowledged. No dividend was declared or discussed in this filing.
Sector / Market Context
India's pharmaceutical capsule manufacturing sector serves both domestic formulators and export markets, with exports accounting for 28.94% of Natural Capsules' FY26 revenue. The Indian pharmaceutical industry, as tracked by the Pharmaceuticals Export Promotion Council of India, has faced variability in African and US export markets in recent periods, a backdrop consistent with the challenges disclosed in this filing.